



SpePharm is developing its pan-European commercial organization and announces the appointment of four Country General Managers

Amsterdam, The Netherlands, 04 February 2008 – SpePharm Holding, B.V., the specialty pharmaceutical company dedicated to the sales and marketing of innovative specialist and hospital products throughout Europe announces the development of its European organization. With the launch of four subsidiaries covering the main European markets, the company is in line with its goal to build a pan-European organization ready for the imminent launch of Loramyc®, its first product, in Europe.

Spepharm Holding B.V. now counts four additional commercial subsidiaries in the EU:

- SpePharm GmbH, headed by Dr. Andreas Heuser, appointed on December 1st 2007.
- SpePharm UK Ltd, headed by Michael Stowe, appointed on January 1st 2008.
- SpePharm Nordic Asp, headed by Peter Sjösten, appointed on January 1st 2008.
- SpePharm Italia s.r.l., headed by Dr Ettore Marre, appointed on February 1st, 2008.

"I am extremely pleased," commented Jean-François Labbé, CEO of SpePharm B.V., "to welcome Andreas Heuser, Mike Stowe, Peter Sjösten and Ettore Marre as Country General Managers respectively for Germany/Austria and Switzerland, UK & Ireland, the Nordic Countries (Denmark), and, lastly Italy. Each of them brings a vast and first class experience in management, marketing and sales. Their primary task is to set up the affiliates, recruit our local hospital sales forces, launch and promote Loramyc®, and our future products. I wish them every success in these challenging assignments."

-end-

Media contact:

SpePharm

Jean-François LABBE

Managing Director

Tel: +33 (0) 1 56 60 58 60

jean-francois.labbe@spepharm.com

About SpePharm Holding, B.V.

SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam, and its European operations based in Paris, France. SpePharm is an emerging pan-European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines essentially for the hospital markets. Particular areas of therapeutic interest are oncology, haematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. SpePharm was founded in September 2006 by Jean-François Labbé together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-François Labbé is a former top executive at Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management. SpePharm, through its founding management team, has a proven track record of successful development, registration, and/or commercialization of quality therapeutic products in supportive care, oncology and haematology, and in orphan diseases. SpePharm has already established a commercial presence in the UK, Germany, Italy and the Nordic countries ready to launch its first product during 2Q2008.

For more information about SpePharm, please visit the web site at www.spepharm.com